MYLUNG Consortium Part 3: Observational Study

Description

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Conditions

Carcinoma, Non-Small-Cell Lung

Talk to us

Study Overview

On this page

Study Details

Study overview

This longitudinal study looks to quantify the testing timeline, operational barriers, and outcomes of biomarker-guided therapy in a large, community-based, and largely unselected patient population with early stage and advanced stage, treatment-naive non-small cell lung cancer, whether squamous or non-squamous.

Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Longitudinal Prospective RWE Study (MYLUNG Consortium Part 3: Observational Study)

MYLUNG Consortium Part 3: Observational Study

Condition
Carcinoma, Non-Small-Cell Lung
Intervention / Treatment

-

Contacts and Locations

Daphne

Southern Cancer Center, PC, Daphne, Alabama, United States, 36526

Prescott Valley

Arizona Oncology Associates, PC - NAHOA, Prescott Valley, Arizona, United States, 86314

Denver

Rocky Mountain Cancer Center, Denver, Colorado, United States, 80218

Palm Bay

Cancer Care Centers of Brevard, Inc., Palm Bay, Florida, United States, 32901

Pensacola

Woodlands Medical Specialists, PA, Pensacola, Florida, United States, 32503

Chicago Ridge

Affiliated Oncologists, LLC, Chicago Ridge, Illinois, United States, 60415

Niles

Illinois Cancer Specialists, Niles, Illinois, United States, 60714

Silver Spring

Maryland Oncology Hematology, P.A., Silver Spring, Maryland, United States, 20904

Minneapolis

Minnesota Oncology Hematology, P.A., Minneapolis, Minnesota, United States, 55404

Albany

New York Oncology Hematology, P.C., Albany, New York, United States, 12208

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Adult subjects (18 years and older) with newly diagnosed early stage, locally advanced or metastatic non-small cell lung cancer
  • * Must be eligible for systemic therapy based on the treating provider's assessment. If systemic therapy was recommended and documented by the treating provider but the patient declined, they can still be eligible for the study. Patients can be enrolled prior to start of treatment.
  • * Subjects who developed locally advanced or metastatic disease after receiving adjuvant or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of locally advanced or metastatic disease
  • * Subjects must be enrolled within 30 days of initiation of systemic therapy
  • * Signed informed consent
  • * Stage IA at the time of enrollment
  • * Subjects with small cell lung cancer
  • * Subjects with Unknown primary tumor origin

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

US Oncology Research,

Makenzi C. Evangelist, MD, PRINCIPAL_INVESTIGATOR, New York Oncology Hematology

Patrick J. Ward, MD, PRINCIPAL_INVESTIGATOR, Oncology Hematology Care Clinical Trials, LLC

Study Record Dates

2030-12